HS-20093 injection
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HS-20093 injection, covering 2026-03-11 to 2026-03-11. Get the full timeline:
Most recent: Clinical Trial Update: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations [Phase 3]